Sarepta Therapeutics Competitors and Similar CompaniesClear all

Sarepta Therapeutics's competitors and similar companies include Lannett, Ionis Pharmaceuticals, Moderna, CureVac, Alnylam and Regulus Therapeutics.

	Sarepta Therapeutics Sarepta Therapeutics is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapeutics, gene therapy and, other genetic therapeutic modalities for the treatment of rare diseases.	Lannett Lannett is a company that specializes in pharmaceutical product families.	Ionis Pharmaceuticals Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics.	Moderna Moderna (formerly Moderna Therapeutics) is a biotechnology company focused on messenger RNA (mRNA) medicine.	CureVac CureVac is a biotechnology company offering messenger RNA (mRNA) technology.	Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments.	Regulus Therapeutics Regulus Therapeutics is a biopharmaceutical company involved in the R&D of high-impact medicines based on microRNAs.
Founding Date	Founding Date 1980	Founding Date 1942	Founding Date 1989	Founding Date 2010	Founding Date 2000	Founding Date 2002	Founding Date 2007
Type	Type Public	Type Public	Type Public	Type Public	Type Public	Type Public	Type Public
Tags	Tags Healthcare biotech drug development genetics	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development genetics pharma	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech pharma	Tags Healthcare biotech drug development pharma
Locations	Locations Cambridge, US HQ Dublin, IE Zug, CH Providence, US	Locations Trevose, US HQ Philadelphia, US	Locations Carlsbad, US HQ	Locations Cambridge, US HQ Melbourne, AU Paris, FR München, DE Tokyo, JP Seoul, KR Warszawa, PL see more	Locations Tübingen, DE HQ Ottignies Louvain La Neuve, BE Wiesbaden, DE Amsterdam, NL Basel, CH Boston, US	Locations Cambridge, US HQ Paris, FR Milan, IT Tokyo, JP Amsterdam, NL Stockholm, SE Zug, CH see more	Locations San Diego, US HQ
Employees	Employees 1,31413% increase	Employees 56031% decrease	Employees 92716% increase	Employees 5,60044% increase	Employees 999	Employees 1,32324% increase	Employees 2462% decrease
Valuation ($)	Valuation ($) 12.4 b	Valuation ($) 7.4 m	Valuation ($) 6.3 b	Valuation ($) 21.2 b	Valuation ($) 648.3 m	Valuation ($) 36.5 b	Valuation ($) 105.4 m
Financial
Revenue (est.)	Revenue (est.) $1.9b (FY, 2024)	Revenue (est.) $340.6m (FY, 2022)	Revenue (est.) $705.1m (FY, 2024)	Revenue (est.) $3.2b (FY, 2024)	Revenue (est.) €53.8m (FY, 2023)	Revenue (est.) $2.2b (FY, 2024)	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods $294.5m (FY, 2022)	Cost of goods $11.2m (FY, 2024)	Cost of goods $1.5b (FY, 2024)	Cost of goods €64.3m (FY, 2023)	Cost of goods $306.5m (FY, 2024)	Cost of goods N/A
Gross profit	Gross profit N/A	Gross profit $33.2m (FY, 2022)	Gross profit $693.9m (FY, 2024)	Gross profit $1.8b (FY, 2024)	Gross profit (€2.6m) (FY, 2023)	Gross profit $1.9b (FY, 2024)	Gross profit N/A
Net income	Net income $235.2m (FY, 2024)	Net income ($231.6m) (FY, 2022)	Net income ($453.9m) (FY, 2024)	Net income ($3.6b) (FY, 2024)	Net income (€260.2m) (FY, 2023)	Net income ($278.2m) (FY, 2024)	Net income ($30m) (FY, 2023)
Operating ⚠
Patent Applications	Patent Applications N/A	Patent Applications N/A	Patent Applications N/A	Patent Applications 430 (FY, 2021)	Patent Applications 500 (Mar, 2020)	Patent Applications N/A	Patent Applications N/A
Patents Issued	Patents Issued N/A	Patents Issued N/A	Patents Issued N/A	Patents Issued 270 (FY, 2020)	Patents Issued 233 (May, 2020)	Patents Issued N/A	Patents Issued 300 (FY, 2016)
Phase I Trials Products	Phase I Trials Products N/A	Phase I Trials Products N/A	Phase I Trials Products 1 (FY, 2023)	Phase I Trials Products N/A	Phase I Trials Products 3 (May, 2020)	Phase I Trials Products N/A	Phase I Trials Products N/A
Funding
Total funding raised	Total funding raised N/A	Total funding raised N/A	Total funding raised N/A	Total funding raised $ 1.8b	Total funding raised $ 1.1b	Total funding raised $ 1.5b	Total funding raised $ 10m